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Movement of HIV-1 Rev between the nucleus and cytoplasm is essential to its function. While normally nuclear, the protein
can be induced to accumulate in the cytoplasm upon inhibition of RNA polymerase I/II. Nuclear accumulation of Rev in the
presence of these inhibitors was found to be rescued upon addition of leptomycin B, an inhibitor of Rev nuclear export. This
finding, in conjunction with kinetic data on nuclear import, indicates that the effect of the RNA polymerase inhibitors is due
to an inversion of the rates of nuclear import versus export possibly achieved by increasing the rate of Rev nuclear export.
We also examined whether changes in Rev localization could be due to a stress response. While neither ultraviolet radiation
nor heat shock affected Rev subcellular localization, both oxidative and osmotic shocks induce changes in Rev localization
comparable to that observed with the RNA polymerase inhibitors. The ability of certain serine/threonine kinase inhibitors,
including CKI/II inhibitors, to cause cytoplasmic accumulation of Rev suggested that the alteration in Rev distribution could
be due to changes in Rev or CRM1 phosphorylation. However, no change in extent of phosphorylation of either protein is
observed upon treatment of cells with any of the agents tested, indicating involvement of another cellular factor. © 2001
Academic Press
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The regulation of RNA metabolism at the levels of
splicing and RNA transport is critical to the replication of
the human immunodeficiency virus (HIV-1). The 9-kb pri-
mary transcript of HIV-1 can be processed into un-
spliced, singly spliced, or doubly spliced transcripts to
generate .25 mRNAs (Schwartz et al., 1990; Wong-Staal,
990). In addition to control at the level of RNA splicing,
ransport of viral RNA is also regulated (Emerman et al.,
989; Felber et al., 1989; Hammarskjo¨ld et al., 1989;
alim et al., 1989b). The unspliced and singly spliced
RNAs are sequestered in the nucleus in the absence of
n essential accessory protein of HIV, Rev (Sodroski et
l., 1986; Feinberg et al., 1986). Rev transports the un-
pliced and singly spliced mRNAs to the cytoplasm,
here they are translated into the structural proteins of
he virus. Rev accomplishes this task through the action
f various functional domains: (1) a nuclear localization
ignal (NLS) that directs Rev import into the nucleus
Cochrane et al., 1990b; Malim et al., 1989a; Perkins et al.,
989; Hope et al., 1990), (2) a RNA binding region that
nteracts with its target HIV RNA in the nucleus (Co-
hrane et al., 1990a; Hadzopoulou-Cladaras et al., 1989;
eaphy et al., 1990; Malim et al., 1989b; Rosen et al.,
988; Zapp and Green, 1989), and (3) a nuclear export
ignal (NES) that targets the Rev-RNA complex to the
ytoplasm (Fischer et al., 1995; Meyer et al., 1996). Ther1 To whom reprint requests should be addressed. Fax: (416) 978-
885. E-mail: alan.cochrane@utoronto.ca.
199resence of both an NLS and NES permits Rev to shuttle
etween the nucleus and cytoplasm of a cell, but it
ccumulates primarily in the nucleus and nucleolus (Co-
hrane et al., 1990b; Malim et al., 1989a; Perkins et al.,
989; Hope et al., 1990). However, various inhibitors of
NA polymerase I and II, such as actinomycin D (Act. D),
ichlorobenzimidizole riboside (DRB), or mycophenolic
cid (MPA), cause Rev to redistribute to the cytoplasm,
eaving little Rev staining in the nucleus (D’Agostino et
l., 1995; Kalland et al., 1994; Meyer and Malim, 1994;
ichard et al., 1994; Wolff et al., 1995). Redistribution to
the cytoplasm under these conditions requires a func-
tional NES (Meyer and Malim, 1994; Stauber et al., 1995;
zilvay et al., 1995).
Subcellular localization is one of many means of reg-
lating protein activity (Turpin et al., 1999; Vandromme et
l., 1996). Several proteins dramatically alter their sub-
ellular localization in response to cell stresses such as
eat or osmotic shock (Hood and Silver, 1999). Changes
n localization can have significant effects on a protein’s
ctivity, altering its ability to interact with substrates or
nhibitors. Given the requirement for Rev to continuously
huttle between the nucleus and cytoplasm, it is of in-
erest to understand how Rev subcellular localization is
egulated. Nucleocytoplasmic shuttling of Rev involves
nteraction with soluble cellular factors that mediate
ev’s interaction with the nuclear pore complex (NPC)
nd execute transport through the nuclear pore. In the
ytoplasm, the arginine-rich NLS interacts with an import
eceptor, importin b, which docks onto the NPC (Truant
and Cullen, 1999; Palmer and Malim, 1999). In the nu-
0042-6822/01 $35.00
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200 SOROS AND COCHRANEcleus, the leucine-rich NES of Rev interacts with an
export receptor, CRM1 (exportin-1), which docks onto the
NPC in a Ran-GTP-dependent manner (Fornerod et al.,
997; Fischer et al., 1995). The antifungal antibiotic lep-
omycin B (LMB) blocks the interaction between the Rev
ES and CRM1, preventing nuclear export of Rev (Wolff
t al., 1997).
To further understand the mechanism underlying Rev’s
edistribution in response to inhibition of RNA polymer-
se I/II, we used LMB to demonstrate that redistribution
nduced by the polymerase inhibitors is reversible, the
esult of an alteration in the relative rates of import and
xport. We also established that oxidative and osmotic
hocks as well as CKI/II inhibitors induce changes in Rev
ocalization comparable to that observed with the RNA
olymerase inhibitors. Effects of the kinase inhibitors on
ev subcellular localization can be ascribed to an alter-
tion in the relative rates of transport into and out of the
FIG. 1. Rev accumulation in the cytoplasm is due to a change in rela
in response to RNA polymerase I/II inhibitors (left) but re-accumulates
untreated (a, b, and c), or treated for 1 h with 4 mg/ml Act. D (d, e, and f)
in the nucleus of Act. D (f and i)- or DRB (l)-treated cells upon addition of
and treated as indicated. Upon RNA polymerase II inhibition by 4 mg/ucleus given the reversibility of their effect upon treat-
ent with LMB. Neither Rev nor CRM1 show alteration in
l
1phosphorylation upon treatment of cells associated with
changes in Rev subcellular distribution, suggesting that
the effect of the kinase inhibitors is mediated by an as
yet unidentified cellular target, which regulates nucleo-
cytoplasmic trafficking.
RESULTS
Cytoplasmic accumulation of Rev is reversed upon
leptomycin B addition
Rev accumulates in the cytoplasm of cells treated with
the RNA polymerase inhibitors Act. D and DRB
(D’Agostino et al., 1995; Kalland et al., 1994; Meyer and
alim, 1994; Richard et al., 1994; Wolff et al., 1995) (also,
ig. 1). To ascertain whether Rev accumulation in the
ytoplasm of treated cells is due to changes in the
ctivity of its NLS, an inhibitor of Rev nuclear export,
eptomycin B (LMB), was tested for its effect on Rev
es of nuclear import versus export. Rev redistributes to the cytoplasm
ucleus upon subsequent addition of LMB (right). HeLaRev cells were
/ml Act. D (g, h, and i), or 150 mM DRB (j, k, and l). Rev re-accumulated
LMB to the media for 1 h. Cells were co-stained for hnRNPA1 (middle)
D, a slight increase in cytoplasmic hnRNPA1 is visible.tive rat
in the n
, 0.4 mgocalization. HeLaRev cells were treated with Act. D for
h, at which point LMB was added to the media for 1 h.
c
i
c
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201HIV-1 REV TRANSPORT AND CELL STRESSAs shown in Fig. 1, Rev within the cytoplasm of Act.
D-treated cells is capable of nuclear import as subse-
quent addition of LMB results in accumulation of Rev in
the nucleus. Nuclear re-accumulation of Rev upon addi-
tion of LMB was complete in 10 min (Table 1). The rapid
nuclear import of Rev in the presence of Act. D and LMB
suggests that cytoplasmic accumulation of the protein is
due to an inversion in the relative rates of Rev nuclear
export versus nuclear import. Additional tests demon-
strated that the kinetics of Rev nuclear accumulation
upon addition of LMB was the same in the presence of
its target RNA (data not shown), indicating that formation
of the RNA–protein complex does not affect Rev shuttling
behaviour.
In support of the conclusion that cytoplasmic accumu-
lation of Rev is not attributable to activation of cytoplas-
mic retention or inactivation of its nuclear import, the
SV40 large T antigen NLS (SVNLS) was fused to the
amino terminus of Rev, creating SVNLSRev (Fig. 2A).
Recent studies (Truant and Cullen, 1999; Palmer and
Malim, 1999) have determined that both the NLS of Rev
and the SV40 large T antigen share a common factor in
their mechanism of import, importin b. Consequently, if
changes in Rev distribution are attributable to changes in
rates of import, the SV40 NLS may be equally affected. In
contrast to Rev, SVNLSRev accumulates in the nucleus
in the presence of Act. D or DRB (Fig. 2B). If cytoplasmic
accumulation of Rev had been due to anchoring of the
protein in the cytoplasm rather than alteration in trans-
port rates, the SVNLS would not be able to rescue Rev
TABLE 1
Kinetics of Leptomycin B Reversal of Actinomycin D-Induced
Accumulation of Rev in the Cytoplasm
Time after Lept. B
addition (min)
Rev subcellular distribution
N . C
(%)
N 5 C
(%)
N , C
(%)
0 0 49 51
10 66 31.8 2.2
15 74 26 0
20 80 20 0
30 68 32 0
Note. HeLa Rev cells were treated for 2 h with 4 mg Act. D/ml and 20
mg/ml cycloheximide at which time leptomycin B was added to a final
concentration of 200 nM. Cells were fixed at the indicated times after
leptomycin B addition and the subcellular localization of Rev deter-
mined by immunofluorescence. Data shown is derived from scoring a
minimum of 100 cells per time point as to the pattern of Rev distribution
observed and is representative of 4 independent trials. N . C signifi-
ant accumulation of Rev in the nucleus, little or no staining apparent
n the cytoplasm. N 5 C equivalent staining of Rev in the nucleus and
ytoplasm. N , C accumulation of Rev in the cytoplasm with little or no
taining in the nucleus.import into the nucleus. Subsequent heterokaryon as-
says show that SVNLSRev equilibrates between humanand mouse nuclei of fused cells (Fig. 2C) confirming the
ability of the fusion protein to shuttle. Finally, SVNLSRev
was found to induce Rev-dependent expression to a
similar extent as unmodified Rev (data not shown). Thus,
addition of the SVNLS does not appear to affect Rev
tertiary folding or its ability to shuttle but does rescue
Rev nuclear accumulation in Act. D-treated cells.
To determine whether the inversion of Rev transport
rates is due to an increase in Rev export rate alone or an
attendant decrease in Rev import, a washout experiment
was performed. The effects of DRB are reversible upon
washing of the cells (Meyer and Malim, 1994; Richard et
al., 1994). HeLaRev cells treated with DRB to re-localize
Rev to the cytoplasm were (1) subsequently treated with
LMB in the continued presence of DRB or (2) washed
with PBS to remove DRB from the cells, and media
containing LMB then was added. The former group of
cells measures nuclear import under conditions where
nuclear export dominates due to the presence of DRB,
while the latter measures nuclear import in the absence
of DRB and, thus, akin to when nuclear import domi-
nates. Two doses of DRB were tested to determine
whether residual drug present following washing could
be affecting the import rates measured. As presented in
Fig. 3, nuclear re-accumulation of Rev is completed in 3
min under all conditions tested, with no discernible dif-
ference in the rate of Rev nuclear accumulation in the
absence or presence of RNA polymerase inhibitors.
Redistribution of Rev is also induced by oxidative and
osmotic shock
The accumulation of Rev in the cytoplasm of cells
treated with Act. D, DRB, or MPA has been previously
attributed to their common effect, inhibition of RNA poly-
merase I (D’Agostino et al., 1995; Kalland et al., 1994;
Meyer and Malim, 1994; Richard et al., 1994; Wolff et al.,
1995). However, the subcellular distribution of several
proteins is altered in response to various stresses on the
cell (Gorner et al., 1998; Ducret et al., 1999; Hood and
Silver, 1999). To ascertain whether the effect of these
RNA polymerase inhibitors may be mediated by induc-
tion of a stress response, the effect of UV stress, heat
shock, oxidative stress, or hyperosmotic shock on Rev
subcellular distribution was examined. As shown in Fig.
4, treatment of Rev-expressing cells for up to 1 h with UV
or 3 h of heat shock (42°C) had no effect on Rev subcel-
lular distribution. In contrast, oxidative stress induced by
treatment with 4 mM hydrogen peroxide or osmotic
stress induced by 0.6 M sorbitol treatment did result in
the cytoplasmic accumulation of Rev. Relocalization was
complete within 30 min of treatment comparable to that
seen in the presence of Act. D. The non-shuttling nuclear
protein hnRNP C remained nuclear under all conditions
(data not shown), demonstrating that nuclear integrity
persists over the course of these treatments.
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202 SOROS AND COCHRANEHnRNP A1, another shuttling protein whose transport
pathways are distinct from Rev also has an altered dis-
tribution pattern in response to Act. D treatment (Pinol-
Roma and Dreyfuss, 1992). However, hnRNP A1 redistri-
bution is specific to inhibition of RNA polymerase II:
a-amanitin and only high doses (4 mg/ml) of Act. D
nduce a slight increase in its cytoplasmic signal (Fig.
E). To ascertain whether hnRNP A1 also responds to
xidative or osmotic stress, cells were treated with hy-
rogen peroxide or sorbitol and co-stained for Rev and
FIG. 2. Addition of the SV40 large T antigen NLS to Rev rescues its
f SVNLSRev. (B) SVNLSRev remains nuclear upon Act. D or DRB treat
nd f) and their subcellular distribution determined by indirect immuno
(c and d) or 150 mM DRB (e and f). Treatments were done in the prese
as it enters the nuclei of mouse cells fused to human cells transfected
and d), or SVNLSRev (e and f) and then fused with mouse 3T3 cells by
human hnRNP C (b, d, and f). Both Rev and SVNLSRev shuttle betwee
nuclei of mouse cells fused to human cells (indicated by staining for hnR
it unable to exit to nucleus, does not shuttle and cannot be found in mnRNP A1. In agreement with recent findings (van der
ouven van Oordt et al., 2000), hnRNP A1 subcellular
s
pocalization is altered upon osmotic shock but not upon
ny of the other stresses (Fig. 4). While some cytoplas-
ic accumulation of hnRNP A1 is discernable at 0.6 M
orbitol, higher sorbitol concentrations were found to
licit a more dramatic shift in the subcellular localization
f the protein (Fig. 4).
edistribution of Rev induced by kinase inhibitors
Signaling cascades induced in response to various
r import in the presence of RNA polymerase inhibitors. (A) Schematic
os-7 cells were transfected with Rev (a, c, and e) or SVNLSRev (b, d,
cence 48 h later (a and b), or after 2 h of treatment with 4 mg/ml Act.
ycloheximide. (C) SVNLSRev is capable of nucleocytoplasmic shuttling
VNLSRev. HeLa cells were transfected with RevM10 (a and b), Rev (c
eatment. The cells were stained with antibody to Rev (a, c, and e) and
ucleus and cytoplasm of the cell. They can be seen to accumulate in
expressing the protein. M10, harboring a mutation in its NES rendering
nuclei.nuclea
ment. C
fluores
nce of c
with S
PEG tr
n the ntresses involve alteration of the activity of various phos-
hatases and kinases, in particular, one of two stress-
203HIV-1 REV TRANSPORT AND CELL STRESSactivated protein kinase pathways (Toone and Jones,
1998; Ichijo, 1999; Tibbles and Woodgett, 1999). In an
attempt to identify kinases or phosphatases modulated
by hydrogen peroxide or sorbitol involved in signaling
Rev redistribution, HeLaRev cells were treated with a
variety of phosphatase inhibitors (okadaic acid and so-
dium orthovanadate), kinase inhibitors (herbimycin A,
PD98059, wortmannin, genistein, staurosporine, A3, SB
FIG. 3. The rate of Rev nuclear import is not altered upon DRB
treatment. For the unwashed set, HeLaRev cells were treated with 150
mM DRB for 2 h and then 200 nM LMB added for 3–15 min, as indicated.
The unwashed set is representative of nuclear import in the presence
of DRB. For the washed set, HeLaRev cells were treated with 150 or 15
mM DRB to accumulate Rev in the cytoplasm, washed 43 with media,
and then 200 nM LMB added for 3–15 min, as indicated. The washed
cells are representative of nuclear import of Rev in the absence of
inhibitor. For each condition, fields of 100 cells were scored as indi-
cated in Table 1 (primarily cytoplasmic, nuclear, or whole cell). The bar
graphs show that nuclear re-accumulation of Rev upon LMB addition
occurs within 3 min for both.203580, and H89), and an activator of the stress-induced
kinase p38 (anisomycin) (Cano et al., 1996). Table 2outlines the drugs, the category to which they belong,
and the concentrations tested for up to 2 h. All drugs
were tested (1) alone for their effect on Rev subcellular
localization, (2) prior to Act. D, hydrogen peroxide or
sorbitol treatment to determine whether relocalization
could be inhibited, or (3) after Act. D, hydrogen peroxide
and sorbitol treatment to observe whether relocalization
could be reversed. None of the drugs were found to
block or reverse the effects of Act. D, hydrogen peroxide,
or sorbitol treatment on Rev subcellular distribution.
FIG. 4. Oxidative and osmotic shock induce a redistribution in Rev.
Subcellular localization of Rev (left) and hnRNP A1 (right) in HeLaRev
cells in response to various shocks. Neither 1 h UV shock (200 J/m2; a
and b) nor 3 h heat shock (42°C; c and d) have any effect on Rev or
hnRNP A1 distribution. One-hour treatment with 4 mM hydrogen per-
oxide (e and f) induces cytoplasmic accumulation of Rev but not hnRNP
A1. Osmotic shock by treatment with 0.6 M sorbitol (g and h) causes
cytoplasmic accumulation of Rev and increases cytoplasmic signal of
hnRNP A1, while 0.8 M sorbitol dramatically increases the amount of
hnRNP A1 in the cytoplasm (i and j). None of the treatments affected
hnRNP C subcellular distribution (data not shown). All treatments were
performed in the presence of 20 mg/ml cycloheximide.
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204 SOROS AND COCHRANEHowever, two kinase inhibitors, genistein and stauro-
sporine, did elicit an accumulation of Rev in the cyto-
plasm but only at concentrations at which they are gen-
eral, non-specific inhibitors of serine/threonine kinases
(Table 2, Fig. 5A). Like oxidative stress, neither genistein
nor staurosporine induced any changes in hnRNP A1 or
C subcellular localization (data not shown).
Previously, DRB-induced alteration of Rev subcellular
distribution had used doses between 100 and 150 mM
(D’Agostino et al., 1995; Kalland et al., 1994; Meyer and
Malim, 1994; Richard et al., 1994; Wolff et al., 1995).
owever, DRB has been shown to be a potent and
T
Drugs Tested for their Effe
Class Drug
AP kinase activator Anisomycin Activates p54
in activation
Phosphatase inhibitor Okadaic acid PP2A 5 0.1 n
PP1 5 10–15
PP2B 5 5 mM
Sodium orthovanadate Potent inhibito
of tyrosine
specificity
Kinase inhibitors Herbimycin A p60v-src 5 90
no effect on P
PD98059 MEK1 5 5–10
MEK2 5 50 m
SB203580 p38 kinase 5
Wortmannin MLCK 5 0.2 m
Genistein EGFR kinase
p60v-src 5 25
PKC, PKA, S/T
Staurosporine MLCK 5 0.00
PKA 5 0.007
PKC 5 0.0007
PKG 5 0.0085
CaM kinase 5
DRB 5,6-dichloro-1-b-D-
ribofuranosyl-
benzimidazole
CKII 5 6 mM
H89 PKA 5 0.048
PKG 5 0.48 m
MLCK 5 28.3
PKC 5 31.7 m
CKI 5 38.3 mM
CKII 5 137 m
A3 PKG 5 3.8 mM
PKA 5 4.3 mM
CKII 5 5.1 mM
MLCK 5 7.4 m
PKC 5 47 mM
CKI 5 80 mM
Note. Drugs and dose ranges tested for their effect on Rev subce
ells alone, prior to and after Act. D or stress treatment. Indicated
ccumulation of Rev. IC50 values cited are derived from the Ca
albiochem-Novabiochem Corp.pecific inhibitor of the serine/threonine kinase, CKII, at
uch lower concentrations (Zandomeni et al., 1986).
a
dherefore, DRB was tested for its ability to induce cyto-
lasmic accumulation of Rev at 15 and 6 mM in a 2-h time
pan. These concentrations were found to be sufficient
o cause the redistribution of Rev from the nucleus to the
ytoplasm in the majority of cells (Fig. 5A). In light of
hese results, other inhibitors of CKII were then tested for
heir effect on Rev distribution. Both A3 and H89, inhibi-
ors of CKI and CKII (Hidaka and Kobayashi, 1992; Ina-
aki et al., 1986), induced the cytoplasmic accumulation
f Rev within 30 min (Fig. 5A). Subsequent tests in HeLa
nd Cos-7 cells transfected with SVH6Rev and SVH6M10
Malim et al., 1989a) confirmed that redistribution is not
ev Subcellular Distribution
erties (IC50) Doses tried Rev localization
nd MAP kinases; involved
PKs
1 mM Nuclear, nucleolar
10 mM Nuclear, nucleolar
aline phosphatase; inhibitor
atases of general/broad
100 mM Nuclear, nucleolar
PKA
10 mM Nuclear, nucleolar
500 mM Nuclear, nucleolar
100 mM Nuclear, nucleolar
2 mM Nuclear, nucleolar
M 10 mM Nuclear, nucleolar
50 mM Cytoplasmic
s . 100 mM 100 mM Cytoplasmic
10 mM Nuclear, nucleolar
100 mM Cytoplasmic
M
150 mM Cytoplasmic
15 mM Cytoplasmic
6 mM Whole cell to
cytoplasmic
50 mM Nuclear, nucleolar
140 mM Cytoplasmic
10 mM Nuclear, nucleolar
80 mM Cytoplasmic
istribution. All drugs were tested for their effect on Rev in HeLaRev
are the doses of the corresponding drug that caused cytoplasmic
em Signal Transduction Catalog and Technical Resource. 1998.ABLE 2
ct on R
Prop
(JNK) a
of SA
M
nM
r of alk
phosph
0 nm
KC or
mM
M
600 nM
M
5 2.6 m
mM
kinase
13 mM
mM
mM
mM
0.02 m
mM
M
mM
M
M
M
llular d
in boldn attribute unique to the stable cell line, and is depen-
ent on a functional NES (data not shown).
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205HIV-1 REV TRANSPORT AND CELL STRESSThe ability of LMB to reverse the effects of the various
stresses and kinase inhibitors on Rev localization was
also tested. As shown in Fig. 5B, cytoplasmic accumu-
lation of Rev induced by the various drug treatments was
reversed within 15 min of LMB addition. This is the same
time span required for LMB reversal of Act. D effects on
Rev localization.
Changes in Rev subcellular distribution does not
correlate with changes in its phosphorylation
or that of CRM1
The observation that serine/threonine kinase inhibi-
FIG. 5. Effect of kinase inhibitors on Rev localization. (A) HeLaRev ce
RB (c), 6 mM DRB (d), 80 mM A3 (e), or 140 mM H89 (f) in the presence
and stained for Rev. (B) Leptomycin B induces nuclear accumulation o
kinase inhibitors. HeLaRev cells were treated for 1 h with 4 mM H2O2
A3 (e), or 140 mM H89 (f). LMB was then added to a final concent
immunofluorescence. Shown here are samples after 15-min treatmenttors can alter Rev localization, coupled with previous
identification of Rev phosphorylation on serine residues
s
y(Cochrane et al., 1989; Hauber et al., 1988), suggested
hat the redistribution observed could be due to alter-
tions in Rev modification. To determine whether there
as a correlation between changes in Rev localization
nd phosphorylation, Rev-expressing cells were labeled
ith [32P]orthophosphate and then treated with the in-
ucers of Rev relocalization. Rev was immunoprecipi-
ated from all the samples and compared for phosphor-
lation status. As can be seen in Fig. 6A, there is no
lteration in the extent of Rev phosphorylation upon Act.
, DRB, A3, hydrogen peroxide, or sorbitol treatment that
orrelates with the changes in Rev subcellular distribu-
ion. CRM1 was also immunoprecipitated from these
e treated with 100 mM genistein (a), 100 mM staurosporine (b), 15 mM
oheximide for 1 h. Cells were then processed for immunofluorescence
edistributed to the cytoplasm in response to the various stresses and
M sorbitol (b), 100 mM genistein (c), 100 mM staurosporine (d), 80 mM
f 200 nM for 15, 30, 45, or 60 min. Cells were then processed for
MB. All treatments were performed in the presence of cycloheximide.lls wer
of cycl
f Rev r
(a), 0.6amples and did not show any changes in its phosphor-
lation status (Fig. 6B) under the conditions tested.
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206 SOROS AND COCHRANEDISCUSSION
A protein’s activity and function can be regulated by
lterations in its subcellular localization. Regulation of
ubcellular localization of a protein can be mediated by
ost-translational modifications, masking of its NLS or
ES, or changes in its interacting partner(s) (Turpin et al.,
999; Vandromme et al., 1996). Many proteins that play a
ole in stress response are activated or inactivated by
hanges in their subcellular localization (Hood and Sil-
er, 1999; Ducret et al., 1999; Gorner et al., 1998). Other
stimuli induce subcellular redistribution of proteins in-
clude changes in intracellular calcium levels (Zhu and
McKeon, 1999), cell cycle stage (Jin et al., 1998), growth
factors (Biggs et al., 1999), phosphate or glucose starva-
tion (Hood and Silver, 1999), and differentiation. Several
proteins [Rev (D’Agostino et al., 1995; Kalland et al., 1994;
Meyer and Malim, 1994; Richard et al., 1994; Wolff et al.,
1995), hnRNP A1 (Pinol-Roma and Dreyfuss, 1992), HuR
(Fan and Steitz, 1998), and VHL (Lee et al., 1999)] that
interact with RNA show transcription-dependent subcel-
lular localization. Except for the latter example, inhibition
of RNA polymerase I/II increases cytoplasmic levels of
the normally nuclear factor.
Rev normally accumulates in the nucleus and nucleo-
lus of cells. It was initially shown to be a shuttling protein
through treatment of Rev-expressing cells with RNA poly-
merase I inhibitors such as Act. D (D’Agostino et al.,
1995; Kalland et al., 1994; Meyer and Malim, 1994; Rich-
ard et al., 1994; Wolff et al., 1995). After such treatment,
Rev is mainly found in the cytoplasm with little or no
staining of the nucleus. However, the mechanism for Act.
D- or DRB-induced redistribution of Rev was unknown. It
could be due to a block in Rev nuclear import or an
alteration in its rate of nuclear transport in favour of
nuclear export. In this paper, we demonstrate that addi-
FIG. 6. Effect of treatments on Rev and CRM1 phosphorylation. (A)
Rev immunoprecipitated from 32P-labeled HeLaRev cells treated with
various drugs. Shown is protein precipitated from cells that were
untreated (lane 1) or treated for 1 h with 4 mg/ml Act. D (lane 2), 150 mM
DRB (lane 3), 80 mM A3 (lane 4), 4 mM hydrogen peroxide (lane 5), or
0.6 M sorbitol (lane 6). (B) CRM1 immunoprecipitated from 32P-labeled
HeLaRev cells that were untreated (lane 1) or treated for 1 h with 4
mg/ml Act. D (lane 2), 150 mM DRB (lane 3), 80 mM A3 (lane 4), or 0.6
M sorbitol (lane 5).tion of LMB, an inhibitor of Rev nuclear export, to Act. D-
or DRB-treated cells causes Rev to re-accumulate in thenucleus (Fig. 1). This result and the finding that addition
of the SV40 NLS to Rev prevents its cytoplasmic accu-
mulation in response to Act. D suggest that the accumu-
lation of Rev in the cytoplasm in response to the inhibi-
tors can be attributed to an inversion in the rates of
nuclear import and nuclear export as Rev is still capable
of nuclear accumulation. Under normal conditions, the
continuously shuttling Rev accumulates in the nucleus,
presumably due to a greater rate of Rev nuclear import
than nuclear export. Upon Act. D or DRB treatment, Rev
accumulates in the cytoplasm. Addition of the SV40 NLS
blocks relocalization to the cytoplasm by virtue of the
presence of a second, putatively stronger NLS, maintain-
ing a high rate of import. By comparing the time span
required for nuclear re-accumulation after LMB addition
between DRB-treated cells and “washed” cells, we show
that there is no discernible difference in the rate of
nuclear import in the absence or presence of the drug
(Fig. 3). That the rates observed following washing are
not due to the presence of residual drug is suggested by
the similarity in results using minimum doses of DRB
(150 vs 15 mM DRB). These results suggest that the
inversion in nuclear transport rates of Rev may be due to
an increase in the rate of Rev nuclear export alone.
However, it is also possible that it is attributable to an
increase in nuclear export rate accompanied by a simul-
taneous decrease in the rate of nuclear import. More
direct and precise measurement of the rate of Rev nu-
clear import will be required to discriminate between
these two hypotheses.
In support of the former hypothesis is a study exam-
ining the control of the subcellular distribution of the von
Hippel-Lindau tumor supressor gene (VHL). VHL nor-
mally resides in the cytoplasm and accumulates in the
nucleus only upon RNA polymerase II inhibition (Lee et
al., 1999). An interesting aspect of this shuttling protein is
that its nuclear accumulation upon inhibition of RNA
polymerase II has been attributed to a decrease in its
nuclear export rate. This pattern of regulation can be
disrupted by the addition of the Rev NES to VHL. The
fusion protein was found to accumulate in the cytoplasm
both in the absence and presence of RNA polymerase
inhibitors. Nuclear accumulation of the fusion protein in
the presence of Act. D could be induced by addition of
LMB. This observation suggests that the cytoplasmic
accumulation of the VHL-NES protein was due to the
high activity of the Rev NES under conditions when the
nuclear import rate of VHL is normally dominant.
We also demonstrate in this paper that certain
stresses can mimic the Act. D-induced cytoplasmic ac-
cumulation of Rev. Neither heat shock nor UV stress have
an effect on Rev subcellular distribution (Fig. 4). In con-
trast, oxidative shock induced by hydrogen peroxide
treatment and osmotic shock do induce Rev to accumu-
late in the cytoplasm. The effects observed are not at-
tributable to a general release of nuclear factors as the
207HIV-1 REV TRANSPORT AND CELL STRESSnon-shuttling nuclear protein, hnRNP C, remains nuclear
under these conditions. Similarly, the response observed
cannot be attributed to effects on nucleolar function
given that cells stressed or treated with the various
drugs retained nucleolar organization and function (data
not shown). That hnRNP A1 also shows increased cyto-
plasmic signal upon Act. D treatment (Pinol-Roma and
Dreyfuss, 1992) or osmotic stress indicates that these
treatments are having effects on multiple transport path-
ways. However, differences in the extent of protein relo-
calization and the conditions required to elicit the re-
sponse suggest that the mechanisms regulating Rev and
hnRNP A1 transport are distinct.
Exposure of cells to stressful conditions has been
shown to elicit activation of a number of signaling path-
ways, the most predominant involving stress-activated
protein kinases such as the JNK (c-Jun N-terminal ki-
nase) and p38 MAP kinases (Toone and Jones, 1998;
Ichijo, 1999; Tibbles and Woodgett, 1999). Consequently,
various kinase activators/inhibitors and phosphatase in-
hibitors were examined for their effect on Rev subcellular
distribution to probe the involvement of these pathways
in the response of Rev to cell stress. None of the drugs
tested inhibited or reversed the effects of Act. D, DRB,
hydrogen peroxide, or sorbitol. Treatment of cells with
the p38 activator anisomycin, the p38 inhibitor SB
203580, the inhibitor of MEK1, PD98059, or phosphatase
inhibitors had no effect on Rev alone or Rev redistribu-
tion stimulated by Act. D or sorbitol. Of the various kinase
inhibitors initially tested, only genistein and staurospor-
ine had any effect on Rev. However, rather than inhibiting
cytoplasmic accumulation of Rev, they induced it at con-
centrations far above their specificity for tyrosine kinases
and at a level where a non-specific inhibition of kinase
activity is observed. Given that DRB is a CKII inhibitor
with an IC50 of 6 mM, lower dose ranges of DRB were
tested to determine whether its effect on CKII is respon-
sible for redistribution of Rev rather than its effect on
RNA polymerases. As shown in Fig. 5A, both DRB and
two other CKI/II inhibitors, A3 and H89, cause Rev redis-
tribution. Similar to Act. D and DRB, reversal of the
effects of hydrogen peroxide, sorbitol, and the kinase
inhibitors that affect Rev redistribution was observed
upon addition of LMB to the media. In all cases, LMB
reversal was completed within 15 min (Fig. 5B). The
similarity of the responses of Rev to the various treat-
ments suggests that they share a mechanism for altering
the relative rates of Rev import versus export. The spec-
ificity of these inhibitors for serine/threonine kinases and
the previous identification of Rev as being modified on
serine residues (Hauber et al., 1988; Cochrane et al.,
1989) suggested the possibility that changes in Rev sub-
cellular accumulation may correlate with changes in its
phosphorylation. However, as demonstrated in Fig. 6,
neither Rev nor CRM1 showed any changes in the extent
of labeling upon treatment with Act. D, DRB, A3, hydro-gen peroxide, or sorbitol which correlates with changes
in Rev subcellular distribution. In further support of the
conclusion that alteration of Rev phosphorylation is not
involved in its redistribution, a deletion mutant of Rev
lacking the primary phosphorylation sites (Rev84) (Co-
chrane et al., 1989) was found to display similar re-
sponses and did not undergo changes in its phosphor-
ylation (data not shown). Changes in Rev transport rates
would therefore appear to be due to modification of
some other cellular factor(s).
The response of Rev differs markedly from that re-
cently reported for the Net repressor (Ducret et al., 1999).
Like Rev, the Net repressor is a shuttling protein con-
taining an NES that interacts with CRM1. However, the
predominately nuclear accumulation of Net is altered
upon treatment of cells with anisomycin, U.V. and heat
shock but not with hyperosmotic stress (0.6 M sorbitol).
The response of Net to stress was subsequently shown
to be dependent upon JNKK (c-Jun N-terminal kinase
kinase), one of the components of the stress response
pathway (Ichijo, 1999; Tibbles and Woodgett, 1999). Such
differences in response despite the use of a common
export pathway underline the conclusion that the subcel-
lular accumulation of any protein is the result of a com-
plex interplay of factors affecting the nuclear import and
export rates of individual proteins. In the case of Rev, the
cellular context of the transport signals also appears to
play a role in its subcellular localization. It was recently
demonstrated in an astrocyte cell line that Rev accumu-
lates in the cytoplasm but is not impeded from nuclear
entry given the ability of LMB treatment to effect nuclear
accumulation of the protein (Ludwig et al., 1999). It re-
mains to be determined whether the rate of nuclear
import or nuclear export of Rev is affected in these cells.
The basis for change in nuclear export rate of Rev de-
scribed in this paper upon RNA polymerase inhibition,
oxidative, and osmotic shock and upon inhibition of cer-
tain kinases remains to be determined since it cannot be
correlated with alterations in phosphorylation of either
Rev or CRM1 (Fig. 6). Since Rev is crucial to the growth
of HIV, alteration of its location and activity is a potentially
important mechanism by which new anti-viral strategies
can be developed.
MATERIALS AND METHODS
Cell lines and transfections
The HeLaRev cell line used in some of the redistribu-
tion assays was generously provided by M. Malim and
has been previously described (Meyer and Malim, 1994).
This cell line was maintained in Isocove’s modified Dul-
becco’s medium (IMDM) supplemented with 10% fetal
bovine serum (FBS), 50 mg/ml gentamycin sulfate, 2.5
mg/ml amphotericin B, and 1 mg/ml amethopterin.HeLa and Cos-7 cells were maintained in IMDM sup-
plemented with 10% FBS, 50 mg/ml gentamycin sulfate,
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208 SOROS AND COCHRANEand 2.5 mg/ml amphotericin B. For transient expression
tudies, vectors were introduced into either Cos-7 cells
y the DEAE-dextran protocol, as previously described
Cullen, 1988), or HeLa cells by calcium phosphate trans-
ection (Kriegler, 1990). Two days post-transfection, cells
ere used for analysis.
xpression constructs
The plasmids SVH6Rev and SVH6M10 have been pre-
iously described (Olsen et al., 1990, 1991). The plasmid
VNLSH6Rev was generated by PCR using the 59 primer,
9-CCGAA TTCAT GCCTA AGAAG AAGAG GA AGG TT-
AA GACCC TGCAG GAAGA AGCGG AGC-39, that con-
ains the nuclear localization signal of the SV40 large T
ntigen and the 39 primer, 59-CCCCC CTCTA GATCT
TATT CTTTA GTTTC G-39. For the PCR reaction,
VH6Rev was used as the template. The amplicon gen-
rated was digested with EcoRI and inserted into the
coRI/SmaI sites of the vector SVpA, containing the SV40
arly promoter, the small t intron and SV40 polyadenyl-
tion signal. The plasmid pDM128 has also been de-
cribed (Hope et al., 1990).
Drug treatments
Cells were treated with various drugs in the presence
of 20 mg/ml cycloheximide (Sigma) for 30 min or 1 or 2 h
as described. The drugs used in the assays include:
actinomycin D (Sigma), DRB (Sigma), hydrogen peroxide,
sorbitol, anisomycin (Sigma), sodium orthovanadate
(Fisher Scientific), okadaic acid (Sigma), wortmannin
(Sigma), the MEKI inhibitor PD98059 (New England Bio-
labs), herbimycin A (Sigma), genistein (Sigma), stauro-
sporine (Sigma), H89 dihydrochloride (Calbiochem), SB
203580 (Calbiochem), and A3 hydrochloride (Calbio-
chem). Leptomycin B, a generous gift of Novartis and
Minoru Yoshida (Nishi et al., 1994; Kudo et al., 1998), was
used at 200 nM where indicated.
Immunofluorescence and immunoprecipitation
Cells grown on coverslips were processed for immu-
nofluorescence as previously described (Perkins et al.,
1989). Polyclonal antibody to Rev was generously pro-
vided by C. A. Rosen. Monoclonal antibodies 4F4 and
4B10 to hnRNP C and hnRNP A1, respectively, were
generously provided by G. Dreyfuss. Polyclonal antibody
to CRM1 was generously provided by G. Grosveld. Flu-
orescein-labeled anti-rabbit and Texas-Red-labeled anti-
mouse antibodies (Jackson ImmuoResearch, Bio/Can
Scientific) were used to detect the polyclonal and mono-
clonal antibodies, respectively. Immunofluorescence
was detected using a Leica DMR microscope at 3630
magnification.
Cells were labeled for immunoprecipitation studies
35 32with either S-Translabel (ICN) or [ P]orthophosphate
(Amersham). Cells were washed twice with TBS andincubated in Dulbecco’s modified Eagle medium
(DMEM) without L-glutamine and L-methionine (Gibco-
BRL) supplemented with 10% FBS for 1 h prior to addition
of the translabel for 24 h. Cells were washed twice with
TBS and incubated in DMEM without sodium phosphate
and sodium pyruvate (GibcoBRL) supplemented with
0.5% FBS for 1 h prior to addition of the orthophosphate
for 1 h. During 1 h of labeling, cells were treated with the
various drugs as indicated and subsequently harvested
in RIPA buffer (150 mM NaCl, 1% Nonidet-P40, 0.5%
deoxycholate, 0.1% SDS, 50 mM Tris pH 7.5). Samples
were processed for immunoprecipitation as previously
described (Cochrane et al., 1989), using polyclonal anti-
body to Rev or CRM1. Immunoprecipitated material was
fractionated on 5% or 12.5% SDS–PAGE gels and de-
tected by exposure to Phosphor Imager screens (Molec-
ular Dynamics).
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